Masimo Co. (MASI) Stake Lessened by JPMorgan Chase & Co.
JPMorgan Chase & Co. lessened its stake in shares of Masimo Co. (NASDAQ:MASI) by 40.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 130,521 shares of the medical equipment provider’s stock after selling 89,592 shares during the quarter. JPMorgan Chase & Co.’s holdings in Masimo were worth $16,255,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its position in Masimo by 3.2% in the 3rd quarter. SG Americas Securities LLC now owns 24,081 shares of the medical equipment provider’s stock valued at $2,999,000 after buying an additional 756 shares during the last quarter. LSV Asset Management bought a new position in Masimo in the 3rd quarter valued at $1,383,000. Parametrica Management Ltd bought a new position in Masimo in the 3rd quarter valued at $234,000. ING Groep NV boosted its position in Masimo by 42.7% in the 3rd quarter. ING Groep NV now owns 7,337 shares of the medical equipment provider’s stock valued at $914,000 after buying an additional 2,195 shares during the last quarter. Finally, Ownership Capital B.V. bought a new position in Masimo in the 3rd quarter valued at $39,259,000. Institutional investors own 82.74% of the company’s stock.
In other news, COO Anand Sampath sold 30,000 shares of the firm’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $110.00, for a total value of $3,300,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $110.90, for a total value of $221,800.00. The disclosure for this sale can be found here. Insiders sold a total of 309,180 shares of company stock worth $37,570,849 over the last 90 days. 12.60% of the stock is owned by corporate insiders.
Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.02. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The business had revenue of $210.58 million for the quarter, compared to analyst estimates of $207.62 million. During the same period last year, the company earned $0.56 EPS. The firm’s revenue was up 8.9% on a year-over-year basis. On average, research analysts anticipate that Masimo Co. will post 2.92 earnings per share for the current fiscal year.
A number of research analysts have commented on MASI shares. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 17th. Needham & Company LLC started coverage on Masimo in a research report on Friday, September 14th. They issued a “buy” rating on the stock. Stifel Nicolaus increased their price objective on Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Piper Jaffray Companies increased their price objective on Masimo to $120.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research lowered Masimo from a “buy” rating to a “hold” rating in a research report on Friday, November 16th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $119.00.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Institutional Investors
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.